BioCentury | Nov 1, 2019
Politics & Policy

Survey finds Europe top alternative for Chinese life science investors amid CFIUS concerns

A survey of Chinese investors revealed broad concern about U.S. restrictions on foreign investment in the life sciences that is diverting Chinese investments to other countries, with Europe cited as the top alternative for investment....
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the company said that based on the results of dialogue with FDA, it will submit an NDA next quarter...
BioCentury | Jul 27, 2018
Company News

Biogen acquires neuromuscular assets from AliveGen

Biogen Inc. (NASDAQ:BIIB) said it acquired two early stage neuromuscular assets from AliveGen USA Inc. (Thousand Oaks, Calif.) and reported rising U.S. sales of spinal muscular atrophy (SMA) therapy Spinraza nusinersen in its 2Q18 earnings...
BioCentury | Jul 24, 2018
Company News

Biogen acquires neuromuscular assets, reports 2Q earnings

Biogen Inc. (NASDAQ:BIIB) said it acquired two early stage neuromuscular assets from AliveGen USA Inc. (Thousand Oaks, Calif.) and reported rising U.S. sales of spinal muscular atrophy (SMA) therapy Spinraza nusinersen in its 2Q18 earnings...
BioCentury | Aug 8, 2016
Company News

Helsinn adds first cancer therapeutic via MEI deal

Helsinn Healthcare S.A. (Lugano, Switzerland) is expanding its focus in cancer beyond supportive care through a licensing deal with MEI Pharma Inc. (NASDAQ:MEIP) for pracinostat (formerly SB939 ) to treat newly diagnosed acute myelogenous leukemia (AML)....
BioCentury | Sep 28, 2015
Clinical News

Japanese cedar tree pollen Allergy Immunotherapy Tablet: Phase II/III data

...allergic rhinitis showed that sublingual TO-206 met the primary endpoint of improving TCRS vs. placebo. TO-206...
...ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Product: Japanese cedar tree pollen Allergy Immunotherapy Tablet (AIT) ( TO-206...
BioCentury | May 25, 2015
Financial News

GW Pharma financial update

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Business: Neurology, Autoimmune Date announced: 2015-05-15 Note: GW Pharmaceuticals raised $26.9 million through the sale of 240,000 ADSs at $112 to cover the overallotment from its April 28...
BioCentury | Nov 24, 2014
Clinical News

scAAV2/8-LP1-hFIXco: Phase I data

Researchers at the hospital and colleagues reported data from an open-label, dose-escalation, U.S. and U.K. Phase I trial in 10 males ages =18 with severe hemophilia Beta showing that single IV infusions of 2x10 11,...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BioCentury | Sep 22, 2014
Clinical News

Japanese cedar tree pollen allergy immunotherapy tablet: Phase II/III started

...ALK-Abello said partner Torii began a Japanese Phase II/III trial to evaluate TO-206 in about 1,000...
...ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Product: Japanese cedar tree pollen allergy immunotherapy tablet (AIT) ( TO-206...
Items per page:
1 - 10 of 56